Key result
Epirubicin yielded an overall response of 35.3% with /m2 weekly and 50% with /m2 every 3 weeks in advanced breast cancer, with no untoward cardiac toxicities.
Why the study?
Does epirubicin 30 mg/m2 weekly compared to 90 mg/m2 every 3 weeks improve efficacy and reduce cardiac toxicity in women with advanced breast cancer?
Does epirubicin 30 mg/m2 weekly compared to 90 mg/m2 every 3 weeks improve efficacy and reduce cardiac toxicity in women with advanced breast cancer?
Epirubicin demonstrates efficacy in advanced breast cancer with relatively little cardiac toxicity across two different dosing regimens.
Answers are grounded in this paper and cite their sources.
May support epirubicin dosing in advanced breast cancer with low cardiac risk; leaves open optimal schedule confirmation in larger trials.
We evaluated the efficacy of epirubicin in a phase II trial in breast cancer, as well as its cardiac toxicity. The study was carried out on 40 female patients with advanced, metastatic, or recurrent breast cancer. The patients were grouped into two groups: group I received 30 mg/m2 epirubicin weekly, and group II 90 mg/m2 epirubicin every 3 weeks. Cardiac monitoring was by ECG, roentgenography, echocardiography and endomyocardial biopsies. Clinical results were 35.3% overall response in group I, and 50% overall response in group II. No untoward cardiac toxicities were encountered. We conclude that epirubicin is an effective agent in breast cancer with relatively little cardiac toxicity.
No takes yet. Share an insight, caveat, or question.
Mawla et al. (1991) studied Advanced, metastatic, or recurrent breast cancer (n=40). Epirubicin vs. Epirubicin 90 mg/m2 every 3 weeks was evaluated on Overall response. Epirubicin yielded an overall response of 35.3% with /m2 weekly and 50% with /m2 every 3 weeks in advanced breast cancer, with no untoward cardiac toxicities.
Synapse has enriched 10 related papers. Consider them for comparative context: